Table 2.
Comparison of characteristics between 40 mg and 30 mg afatinib groups
| Characteristics | All patients | 40 mg | 30 mg | P |
|---|---|---|---|---|
| N | 60 | 41 | 19 | |
| Age | ||||
| Median (years) | 58.1 | 57.2 | 58.1 | |
| Range | 36.3–82.7 | 36.3–70.9 | 44.6–82.7 | |
| Age distribution, N (%) | ||||
| ≥ 65 | 13 (21.7%) | 6 (14.6%) | 7 (36.8%) | 0.108 |
| < 65 | 47 (78.3%) | 35 (85.4%) | 12 (63.2%) | |
| Gender | ||||
| Male | 30 (50.0%) | 21 (51.2%) | 9 (47.4%) | 0.781 |
| Female | 30 (50.0%) | 20 (48.8%) | 10 (52.6%) | |
| Smoking history | ||||
| Yes | 18 (30.0%) | 13 (31.7%) | 5 (26.3%) | 0.672 |
| No | 42 (70.0%) | 28 (68.3%) | 14 (73.7%) | |
| ECOG PS score | ||||
| 0–1 | 60 (100%) | 41 (100%) | 41 (100%) | — |
| 2–4 | 0 | 0 | 0 | |
| EGFR mutation | ||||
| Exon 19 deletion | 26 (43.3%) | 20 (48.8%) | 6 (31.6%) | 0.370 |
| Exon 21 L858R | 16 (26.7%) | 9 (22.0%) | 7 (36.8%) | |
| Uncommon mutations† | 18 (30.0%) | 12 (29.3%) | 6 (31.6%) | |
| Baseline brain metastasis | ||||
| Yes | 24 (40.0%) | 18 (43.9%) | 6 (31.6%) | 0.365 |
| No | 36 (60.0%) | 23 (56.1%) | 13 (68.4%) | |
| Line of afatinib | ||||
| First line | 39 (65.0%) | 29 (70.7%) | 10 (52.6%) | 0.172 |
| ≥ Second line | 21 (35.0%) | 12 (29.3%) | 9 (47.4%) | |
†
Four patients had both exon 21 L858R and uncommon mutations and one patient had both exon 19 deletion and uncommon mutations. ECOG PS, Eastern Cooperative Oncology Group performance status.